NOVO-NORDISK AS (NVO)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-09
$44.56-1.33%
Close 2026-09-09 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-09
Research Workspace
Put NVO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — EPS at or above $21.6 in FY26: metric not reported.
View ThesisThis stock is volatile — it swings about 1% on a typical day and fell roughly 44% in its worst 12-month stretch.
View RiskNovo Nordisk's growth relies on its ability to leverage AI in drug discovery. The company recently partnered with Amazon Web Services to enhance its operations and efficiency. Revenue growth has been strong, with a 17% beat in the last quarter. Novo Nordisk trades at a P/E of 11.4x, significantly lower than the industry average of 21.7x. This suggests that the market may not fully reflect its growth potential. A specific risk is the impact of a failed heart drug trial, which could significantly affect its valuation. Peer multiples imply a price about 12% below where it trades. Our read is provisional.
Trailing returns as of 2026-09-09. NVO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering NVO (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NVO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NVO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put NVO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Heart trials halt poses risk to product pipeline.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-09. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Phase III terminations hinder product development and market entry.
CEO comments highlight competitive risks from black market peptides.
Earnings doubts could impact stock valuation negatively.
Concerns about Ozempic may hinder future product launches.
Rating downgrade indicates potential negative sentiment affecting stock price.
Obesity drug setbacks could impact valuation significantly.
Analyst downgrade impacts market perception and valuation.
